What is known and Objective: Hypersensitivity adverse drug reactions (HADRs) are associated with considerable morbidity and mortality. The aim of this study was to identify cases of HADRs within a hospital electronic health records (EHR) database. What is new and conclusion: This registry contains HADRs that are relevant for the pharmacovigilance system, but none was spontaneously reported. The responsible authorities should address this problem. The results also reinforce the association between systemic antibacterials and HADRs.
| WHAT IS K NOWN AND OBJEC TIVE
Adverse drug reactions (ADRs) are a leading cause of morbidity and mortality in the healthcare process, with deleterious consequences both for the individual patient and for public health. Two categories of ADRs encompass most cases occurring in clinical practice, namely type A and type B reactions.
1 While the first refers to relatively common, predictable and dose-dependent ADRs, which are usually explained by the mechanism of action of the drug, type B reactions-also called "idiosyncratic reactions"-are less frequent, almost unpredictable and associated with higher morbidity and mortality. Type B reactions are responsible for approximately 15% of all ADRs and include hypersensitivity reactions. 2, 3 Depending on their genesis, hypersensitivity reactions are classified as either allergic reactions, when there is evidence of underlying immunological mechanism (ie drug-specific IgE or IgG antibodies or T cells), or nonimmunological/nonallergic hypersensitivity reactions. 4 Furthermore, hypersensitivity reactions can be classified as immediate or nonimmediate, according to the onset timing of symptoms. Lyell's syndrome, and drug reaction with eosinophilia and systemic symptoms [DRESS] ). [3] [4] [5] [6] Hypersensitivity ADRs represent a significant public health problem. They have been described to affect 10%-20% of hospitalized patients and up to 7% of the general population exposed to drugs. 2 The frequency of drug-induced anaphylaxis was estimated to range between 0.2% and 3.1% in Europe. [7] [8] [9] The registration of these cases in electronic health records (EHRs) is an important contribution for patient safety. 10 This practice allows the characterization of the safety profiles of marketed drugs and may help to prevent further ADRs in certain patients. The aim of this study was to identify and characterize cases of drug-induced hypersensitivity reported in a Portuguese hospital over 5 years.
| ME THODS

| Clinical registry
The Portuguese catalogue of allergies and other adverse reactions (CPARA) was developed to improve the process of collecting and sharing clinical information, particularly hypersensitivity reactions, in a structured and harmonized way across the Portuguese healthcare system. This module is used by physicians and nurses to record hypersensitivity ADRs within the EHR of each patient. This registry applies to patients admitted to hospital because of ADRs and also to inpatients developing ADRs during hospitalization.
However, this variable is not discriminated within the database.
Furthermore, national legislation was put in force to impose the use of CPARA by healthcare professionals to record hypersensitivity reactions.
11,12
The CPARA registry is structured as follows: (a) source of infor- As a single patient may experience more than one hypersensitivity ADR in association with a single suspected drug, the concept of individual case safety report (ICSR) was considered to carry out data analyses. An ICSR refers to "one or several suspected adverse reactions to a medicinal product that occur in a single patient at a specific point of time". 15 Therefore, the number of suspected medicines equals the number of ICSRs. However, the number of patients can be lower than the number of ICSRs, because a patient may experience several cases of ADR in association with different suspected drugs at distinct points of time. Moreover, the number of suspected ADRs can be higher than the number of ICSRs, because a patient may experience more than one ADR in association with each suspected drug.
| Data analysis
Descriptive statistics were used to analyse data. The pattern of suspected drugs involved in anaphylactic reactions was compared with those associated with other hypersensitivity ADRs: odds ratio (OR) with 95% confidence interval (CI) was calculated whenever there were at least five cases of anaphylactic reactions associated with a particular class of suspected drugs (2nd level of ATC classification).
Reporting rate of cases of hypersensitivity ADRs per million inhabitants per year was calculated. Five-year prevalence rates for patients with hypersensitivity ADRs were estimated using total numbers of local inhabitants, and inpatients. Microsoft Office Excel ® 2013
(Microsoft Corp., Redmond, WA, USA) was used.
| RE SULTS
The database contained 484 ICSRs, of which 20 were found to be duplicates. Therefore, a total of 464 cases were valid for inclusion in the study. Of those, 330 (77.1%) were rated as severe. On average, there were 93 cases of hypersensitivity ADRs per year. The highest number of cases recorded in a single year was 115 in 2013, whereas the lowest was 60 in 2015. There were 223 active (48.1%), 126 inactive (27.2%), 61 unconfirmed (13.1%) and 54 confirmed (11.6%) cases.
With respect to the source of information, cases were reported by healthcare professionals (n = 369; 79.5%), patients (n = 93; 20.1%) and specialists in immunological and allergic diseases (n = 2; 0.4%).
The 464 cases corresponded to a total of 380 patients and 559
hypersensitivity ADRs. Therefore, on average, each patient was exposed to approximately 1.2 suspected drugs and experienced nearly 1.5 hypersensitivity ADRs. The median age of patients was 55 years (range 2-98), and 254 (66.8%) were women.
More than half of cases (n = 245; 52.8%) were associated with the use of antibacterials for systemic use (Table 1) , mainly betalactam antibacterials ( Table 2 ). The majority of hypersensitivity ADRs were skin and subcutaneous tissue disorders (n = 266; 47.6%), F I G U R E 1 Diagram representation on the information model of CPARA. Adapted from Ref. [13] such as urticaria (n = 106; 19.0%) and angioedema (n = 61; 10.9%), or immune system disorders (n = 231; 41.3%), namely anaphylactic reactions (n = 209; 37.4%) ( Table 3 ). The pattern of suspected drugs implicated in anaphylactic reactions was the same as for the other hypersensitivity ADRs (Table 4) .
Overall, the reporting rate of cases of hypersensitivity ADRs was estimated at 273 cases per million inhabitants per year.
Approximately 0.1% local inhabitants (380/340 000) and nearly 0.4% inpatients (380/101 500) had experienced hypersensitivity ADRs over the 5-year study period. it should be noted that severity (severe or mild) is not synonymous with seriousness (serious or nonserious). Severity is used to describe the intensity of a given event, but not its clinical significance. Seriousness is defined based on patient's outcome, and it is used to guide regulatory reporting obligations in pharmacovigilance activities. 16 As an example, dyspnoea can be severe during a limited period of time, but simultaneously nonserious if there are not clinically relevant consequences for the patient or medical intervention is not required to resolve it. Seriousness assessment is not performed within the CPARA registry.
| D ISCUSS I ON
The overall 5-year prevalence for patients with hypersensitivity
ADRs among the general population (0.1%) and inpatients (0.4%) is low as compared to previous studies in other settings. 2 It is important to recall that the present study was based on retrospective analysis and that the analysed data come from a single hospital. There is the possibility that some cases were not recorded in the database and that some individuals with hypersensitivity ADRs have been treated in other hospitals. Furthermore, under-reporting of ADRs is a known limitation of spontaneous reporting schemes. 17 There is also the possibility that clinicians do not acknowledge a causal relationship between the exposure to drugs and the development of hypersensitivity reactions. 18 Therefore, the real prevalence of these cases is probably higher than the estimations found here. A retrospective study using EHR data in Boston (USA) found that 0.3% of outpatients have hypersensitivity reactions to nonsteroidal antiinflammatory drugs (NSAIDs) within 1 year of prescription. A single patient may experience more than one case of ADR and more than one ADR per case. For example, a patient experienced eczema and dyspnoea after the administration of benzylpenicillin; other patient experienced three episodes of urticaria: one in association with nimesulide, other with paracetamol and a last one with dexibuprofen. Sum total may not be 100.0% due to rounding. 
TA B L E 4 (Continued)
of ATC) in a considerable proportion of cases (n = 95; 20.5%). This is probably because the healthcare professionals who report the cases were not necessarily the prescribers of suspected drugs, which could make it difficult the access to that information. Other 
| WHAT IS NE W AND CON CLUS I ON
Postmarketing drug safety evaluations should comprehend analyses of data obtained from multiple sources to assure evidencebased decisions. A passive pharmacovigilance approach, which relies mostly on spontaneous reports of suspected ADRs, was found to be insufficient. As noted in this study, cases of hypersensitivity ADRs registered in the EHRs of patients were not reported to the PPS. Responsible health authorities should promote more proactive ways of collecting clinical data to better identify and prevent ADRs, improve benefit-risk assessments, increase patient safety and protect public health. The results also reinforce the fact that antibacterials for systemic use and anti-inflammatory drugs deserve particular attention from clinicians because these therapies were found to be implicated in most cases of hypersensitivity ADRs.
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